Cargando…
Effective, safe, and sustained correction of murine XLA using a UCOE-BTK promoter-based lentiviral vector
X-linked agammaglobulinemia (XLA) is an immune disorder caused by mutations in Bruton’s tyrosine kinase (BTK). BTK is expressed in B and myeloid cells, and its deficiency results in a lack of mature B cells and protective antibodies. We previously reported a lentivirus (LV) BTK replacement therapy t...
Autores principales: | Seymour, Brenda J., Singh, Swati, Certo, Hannah M., Sommer, Karen, Sather, Blythe D., Khim, Socheath, Clough, Courtnee, Hale, Malika, Pangallo, Joseph, Ryu, Byoung Y., Khan, Iram F., Adair, Jennifer E., Rawlings, David J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907679/ https://www.ncbi.nlm.nih.gov/pubmed/33718514 http://dx.doi.org/10.1016/j.omtm.2021.01.007 |
Ejemplares similares
-
Safe and Effective Gene Therapy for Murine Wiskott-Aldrich Syndrome Using an Insulated Lentiviral Vector
por: Singh, Swati, et al.
Publicado: (2016) -
A mutation in the promoter region of BTK causes atypical XLA
por: Bravo García-Morato, María, et al.
Publicado: (2020) -
BTK mutations selectively regulate BTK expression and upregulate monocyte XBP1 mRNA in XLA patients
por: Teocchi, Marcelo A, et al.
Publicado: (2015) -
Limapakgsin ixlilakkaxlan xla pulataman Veracruz xla Ignacio de la Llave
Publicado: (2012) -
Transcriptome profiling of monocytes from XLA patients revealed the innate immune function dysregulation due to the BTK gene expression deficiency
por: Mirsafian, Hoda, et al.
Publicado: (2017)